EC conditionally approves Votrient

The European Commission granted conditional approval to an MAA for Votrient pazopanib from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who received prior cytokine therapy for advanced disease. As part of conditional approval, GSK will provide data from ongoing trials. Votrient is a broad-spectrum inhibitor of VEGF and other tyrosine kinases. ...